Article info

Extended report
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
Free

Authors

  1. Correspondence to Dr J T Merrill, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, 825 NE 13th St., Oklahoma City, OK 73104 USA; joan-merrill{at}omrf.org
View Full Text

Citation

Merrill JT, van Vollenhoven RF, Buyon JP, et al
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Publication history

  • Received March 25, 2015
  • Revised June 18, 2015
  • Accepted August 1, 2015
  • First published August 20, 2015.
Online issue publication 
January 11, 2016

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.